Patents by Inventor Rachael L. Neve

Rachael L. Neve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cloning and expression of .beta.APP-C100 receptor (C100-R)
    Patent number: 6083713
    Abstract: The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: July 4, 2000
    Assignees: Bristol-Myers Squibb Company, McLean Hospital Corporation
    Inventors: Susan P. Manly, Michael R. Kozlowski, Rachael L. Neve
  • .beta. APP-C100 receptor
    Patent number: 5854392
    Abstract: The present invention relates to the cloning of .beta.APP-C100 receptor (C100-R), and genetically engineered host cells which express the C100-R. Such engineered cells may be used to evaluate and screen drugs and analogs of .beta.-APP involved in Alzheimer's Disease.
    Type: Grant
    Filed: August 30, 1993
    Date of Patent: December 29, 1998
    Assignees: Bristol-Myers Squibb Company, McLean Hospital Corporation
    Inventors: Susan P. Manly, Michael R. Kozlowski, Rachael L. Neve
  • Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
    Patent number: 5849999
    Abstract: Disclosed is a transgenic non-human mammal that expresses in its brain a transgene encoding an APP-C100 polypeptide with the flag amino acid sequence fused to the amino terminus of the APP-C100. This transgenic non-human mammal is an improved in vivo model for Alzheimer's disease-like neuropathology and associated cognitive impairment. The improvement includes accelerated development of AD-like neuropathology and cognitive impairment. The AD-like neurodegeneration and associated cognitive impairment in mice produced according to this invention appear at least six months sooner than they appear in APP-C100-expressing transgenic mice.
    Type: Grant
    Filed: October 16, 1996
    Date of Patent: December 15, 1998
    Assignees: The McLean Hospital Corporation, Wellesley College
    Inventors: Rachael L. Neve, Joanne Berger-Sweeney
  • Transgenic mice expressing the neurotoxic C-terminus of .beta.-amyloid precursor protein
    Patent number: 5672805
    Abstract: The present invention provides non-human, transgenic animals for use as a model for the study of Alzheimer's Disease. The animals exhibit pathology associated with Alzheimer's Disease. The phenotype is conferred in the animals by the introduction of an amyloid-containing polypeptide fragment of amyloid precursor protein, through the introduction of the DNA into the germ and somatic cells of the animal by transgenic methods.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: September 30, 1997
    Assignee: The Regents of the University of California
    Inventor: Rachael L. Neve